96976 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Interleukins [IL] IL-2
Gene therapy vectors and cytosine deaminases
#902Ligands modified by circular permutation as agonists and antagonists
#903Methods and compositions relating to improved lentiviral vectors and their applications
#904Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
#905Immunocytokine combination therapy
#906Protein expression
#907USE OF IL-12 TO GENERATE ENDOGENOUS ERYTHROPOIETIN
#908Method for treating a GD2 positive cancer
#909DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
#910Antagonists of interleukin-2 receptor
#911INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF
#912Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity
#913Methods for regulating protein function in cells in vivo using synthetic small molecules
#914Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
#915Fusion polypeptides comprising mucin-domain polypeptide linkers
#916Ligands modified by circular permutation as agonists and antagonists
#917Immunomodulatory methods and systems for treatment and/or prevention of hypertension
#918Method of treating graft versus host disease using IL-2 muteins
#919Heterodimeric human IgG1 polypeptides with isoelectric point modifications
#920Modified SAK gene for the production of recombinant proteins
#921Methods and compositions relating to improved lentiviral vectors and their applications
#922T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF
#923Methods for Treating Vascular Leak Syndrome and Cancer
#924High affinity NY-ESO T cell receptors
#925Method of cancer treatment
#926METHODS FOR ENHANCING THE EFFICACY OF IL-2 MEDIATED IMMUNE RESPONSES
#927METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2 AND IL2 IN PATIENTS
#928Immunomodulatory interleukin-2 polypeptides and methods of treating melanoma
#929Reducing the immunogenicity of fusion proteins
#930Immunoconjugates
#931Mutant interleukin-2 polypeptides
#932Alteration of cell membrane for new functions
#933TH1/TH2 polarizing vaccines
#934Method for treating cancer by administering IL-15 and IL-15Ralpha complexes
#935Methods for obtaining molecules with reduced immunogenicity
#936Method of Producing Hydroxyalkyl Starch Derivatives
#937Albumin fusion proteins
#938MEANS AND METHOD FOR THE TREATMENT OF ANTIBODY DEFICIENCY DISEASES BASED ON IL-21 AND IL-21 VARIANTS
#939Mutant interleukin-2 (IL-2) polypeptides
#940COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES
#941IMPROVED PRODUCTION OF PROTEINS WITH DOWNSTREAM BOX FUSIONS IN PLASTIDS AND IN BACTERIA
#942High affinity NY-ESO T cell receptors
#943ALLOGENEIC VACCINE AND METHODS TO SYNTHESIZE SAME
#944Cysteine variants of interferon gamma
#945Gene therapy vectors and cytosine deaminases
#946ALLOGENEIC VACCINE AND METHODS TO SYNTHESIZE SAME
#947Interleukin-2/soluble TGA-beta type II receptor B conjugates and methods and uses thereof
#948METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2, AND IL2 IN PATIENTS
#949Polymer Particles and Uses Thereof
#950Methods of using interleukin-2 mutants with reduced toxicity
#951Mutant interleukin-2 (IL-2) polypeptides
#952T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THERE OF
#953Hydroxyalkyl starch derivatives
#954METHODS AND COMPOSITIONS FOR EXPANDING T REGULATORY CELLS
#955High affinity NY-ESO T cell receptor
#956METHODS AND COMPOSITIONS FOR MODIFYING T CELL IMMUNE RESPONSES AND INFLAMMATION
#957High affinity NY-ESO T cell receptors
#958Albumin fusion proteins
#959Method of Producing Hydroxyalkyl Starch Derivatives
#960Compositions and methods for treatment of angiogenesis in pathological lesions
#961COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND /OR THEIR CANCEROUS COUNTERPART
#962INVENTION CONCERNING THE EXPRESSION AND PERMANENT RELEASE OF CANINE INTERLEUKINES
#963Viral particles encoding multifunctional cytokines
#964Method of cancer treatment
#965Multifunctional Cytokines
#966Multi-modal cancer therapy using viral hitch-hiking
#967Cytokine-based fusion proteins for treatment of multiple sclerosis
#968Methods and compositions relating to improved lentiviral vectors and their applications
#969Mutant interleukin-2 (IL-2) polypeptides
#970Method for regulating protein function in cells in vivo using synthetic small molecules
#971Reducing the immunogenicity of fusion proteins
#972CHIMERIC PROTEINS WITH CELL-TARGETING SPECIFICITY AND APOPTOSIS-INDUCING ACTIVITIES
#973Therapeutic use of interleukin-2 mutants
#974Immunotherapeutic Formulations with Interleukin-2-Neutralizing Capacity
#975Enhancing the circulating half-life of antibody-based fusion proteins
#976IRX-2 modified manufacturing process
#977Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
#978MOLECULES AND CHIMERIC MOLECULES THEREOF
#979Albumin Fusion Proteins
#980DNA encoding IL-2 fusion proteins with modulated selectivity
#981Albumin Fusion Proteins
#982Alteration of cell membrane with FasL
#983DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
#984Anti-IL2 antibodies
#985Cysteine variants of interferon gamma
#986Viral/bacterial toxin polypeptides and methods of using same
#987Ligands and libraries of ligands
#988Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
#989Cysteine variants of interferon-gamma
#990Albumin fusion proteins
#991Albumin Fusion Proteins
#992Albumin fusion proteins comprising insulin polypeptides
#993Albumin Fusion Proteins
#994G-CSF-albumin fusion proteins
#995Albumin fusion proteins
#996METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2, AND IL2 IN PATIENTS
#997Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine
#998Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
#999Methods for enhancing the efficacy of IL-2 mediated immune responses
#1000Rapid screening method of translational fusion partners for producing recombinant proteins and translational fusion partners screened therefrom
#1001Albumin fusion proteins
#1002Methods of targeting multiple cytokines
#1003Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
#1004Albumin fusion proteins
#1005Methods for promoting, inhibiting and detecting toxin entry into cells
#1006Stabilized Peptides
#1007Methods and compositions relating to restricted expression lentiviral vectors and their applications
#1008Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
#1009Methods and compositions for expanding T regulatory cells
#1010Anth1 chimeric antagonist
#1011Compositions and methods for cancer immunotherapy
#1012Combination gene for use in inhibiting cancerous cell growth
#1013Multifunctional cytokines
#1014Binding molecules
#1015Cancer treatments including administering IL-2 fusion proteins with modulated selectivity
#1016Metal chelate complexes immobilized on solid supports for peptide preparation
#1017Erythropoietin: remodeling and glycoconjugation of erythropoietin
#1018Latent fusion protein
#1019Therapeutic use of interleukin-2 mutants
#1020Remodeling and glycoconjugation of peptides
#1021Albumin fusion proteins
#1022Interleukin-2 muteins
#1023Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
#1024In vitro test system for predicting patient tolerability of therapeutic agents
#1025Method for improving recovery yield in protein purification with gel filtration chromatography
#1026Albumin fusion proteins
#1027IL-2 transmembrane construct
#1028Combinatorial interleukin-2 muteins
#1029Viral vectors and the use of the same for gene therapy
#1030Process for concentration of macromolecules
#1031Methods of treating tumors using natural killer cell lines
#1032Compositions and methods for modifying toxic effects of proteinaceous compounds
#1033Chimeric antagonist anth1
#1034Enhancing the circulating half-life of antibody-based fusion proteins
#1035Method for the genetic activation of cells and uses of said cells
#1036Reducing the immunogenicity of fusion proteins
#1037Hasylated polypeptides
#1038Method for inducing selected useful activities of IL-2 in a patient with peptides from IL-2
#1039Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
#1040Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
#1041Allogeneic vaccine and methods to synthesize same
#1042Method of producing hydroxyalkyl starch derivatives
#1043Hydroxyalkyl starch derivatives
#1044Cysteine substitution variants of beta interferon
#1045Soluble TCR molecules and methods of use
#1046COOH-terminally added cysteine variant of the beta interferon
#1047Interleukin-2 mutants with reduced toxicity
#1048Albumin fusion proteins comprising GLP-1 polypeptides
#1049Allogeneic vaccine and methods to synthesize same
#1050Mutant interleukin-2 (IL-2) polypeptides
#1051Cysteine variants of erythropoietin
#1052Pharmaceutical compositions of glycoconjugates
#1053Cysteine variants of erythropoietin
#1054Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
#1055Enhancing the circulating half-life of interleukin-2 proteins
#1056Plasmids suitable for IL-2 expression
#1057Multifunctional cytokines
#1058Methods for obtaining molecules with reduced immunogenicity
#1059Cultured stromal cells and uses thereof
#1060Novel synthetic chimeric fusion transgene with immuno-therapeutic uses
#1061Fusion proteins containing tlp peptides
#1062DNA vaccine containing tumor-associated gene and cytokine gene and method of preparation the same
#1063Immune-stimulating IL-2 fusion proteins
#1064IL-2 muteins
#1065IL-2 muteins
#1066Antibodies and immunocytokines
#1067Modified IL-2 variants that selectively activate regulatory T cells
#1068Natural killer cell lines and methods of use